We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Date
- 2024 (32)
- 2023 (48)
- 2022 (26)
- 2021 (102)
- 2020 (61)
- 2019 (127)
- 2018 (41)
- 2017 (22)
- 2016 (26)
- 2015 (14)
- 2014 (22)
- 2013 (8)
- 2012 (3)
- 2010 (2)
- 2009 (12)
- 2008 (6)
- 2007 (12)
- 2006 (11)
- 2005 (15)
- 2004 (5)
- 2003 (2)
- 2002 (6)
- 2001 (4)
- 2000 (12)
- 1999 (5)
- 1998 (4)
- 1997 (1)
- 1996 (9)
- 1995 (2)
- 1994 (6)
- 1993 (6)
- 1991 (23)
Results for
"[search-keyword]"
Sponsor content
675 result(s) found, displaying 1 to 10
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Australian Public Assessment Report (AusPAR)Xenpozyme (olipudase alfa) has been approved as an enzyme replacement therapy for the treatment of noncentral nervous system manifestations of acid sphingomyelinase deficiency in paediatric and adult patients with Niemann-Pick disease (types A/B or B).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for XENPOZYME olipudase alfa 4mg powder for injection vial.
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd